Claims for Patent: 9,297,812

Summary for Patent: 9,297,812

Title:	Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
Abstract:	The present invention relates to the field of diagnostic tests and diagnostic tools. Specifically, contemplated is to a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising contacting the sample with an antibody which specifically binds to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide under conditions which allow for binding of said antibody to the epitope and determining binding of the antibody to the epitope, whereby cancer is diagnosed. Further contemplated are antibodies which specifically bind to the epitope characterized by SEQ ID NO 1 on a BRAF polypeptide and a device or kit comprising such antibodies.
Inventor(s):	Zentgraf; Hanswalter (Heidelberg, DE), Von Deimling; Andreas (Schriesheim, DE), Capper; David (Mannheim, DE)
Assignee:	Deutsches Krebsforschungzentrum (Heidelberg, DE) Ruprecht-Karl-Universitat Heidelberg (Heidelberg, DE)
Application Number:	13/877,035
Patent Claims:	1. The antibody produced by the cell line deposited under accession number DSM ACC 3091. 2. A device for diagnosing cancer comprising a) an analyzing unit comprising the antibody of claim 1, wherein said analyzing unit allows for the determination of specific binding of the antibody to the epitope characterized by SEQ ID NO: 1 in the BRAF polypeptide in a sample applied to the analyzing unit; and b) an evaluation unit which comprises implemented rules for evaluating the binding determined by the analyzing unit and for establishing a diagnosis. 3. The device of claim 2, wherein said sample is a tissue sample. 4. The device of claim 3, wherein said tissue sample is a tissue section sample. 5. A kit for diagnosing cancer comprising the antibody of claim 1. 6. A method for diagnosing cancer in a sample of a subject suspected to suffer from cancer comprising: a) contacting the sample with the antibody of claim 1 under conditions which allow for binding of said antibody to the epitope; and b) determining binding of the antibody to the epitope, whereby cancer is diagnosed. 7. The method of claim 6, wherein said diagnosing cancer comprises determining the presence or absence of cancer cells. 8. The method of claim 7, wherein said cancer cells are within a tissue sample. 9. The method of claim 8, wherein said tissue sample is a tissue section sample. 10. The method of claim 6, wherein said method further comprises the step of recommending, or not, an anti-cancer therapy based on the diagnosis obtained in step b). 11. The method of claim 10, wherein said anti-cancer therapy is selected from the group consisting of: anti-BRAF antisense RNA, siRNA or micro RNA drugs, anti-BRAF antibodies, sorafenib, RAF-265,PLX-4032, cetuximab and GDC-0879.

Details for Patent 9,297,812

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26